Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (6116)	7/14/2001 12:44:33 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

lots of old discussion -- in this thread -- relating to this project and its' chances........ Thursday July 12, 6:30 pm Eastern Time Press Release SOURCE: Weiss & Yourman Class Action Securities Lawsuit Filed Against Immune Response Corp. And Agouron Pharmaceuticals LOS ANGELES, July 12 /PRNewswire/ -- Weiss & Yourman announced today that it has filed a class action complaint on behalf of all persons who acquired Immune Response Corp. (Nasdaq: IMNR - news) securities between May 17, 1999 and July 6, 2001, inclusive (the ``Class Period''). The complaint charges Immune Response Corp. and Agouron Pharmaceuticals, Inc. and their top officers with violations of federal securities laws. Immune is a biopharmaceutical company developing immune-based therapies to induce specific T cell response for the treatment of HIV, autoimmune diseases, gene therapy and cancer. Immune's major product is Remune, an injectable HIV-1 immunogen-based treatment designed to slow or stop the progression of HIV infections into AIDS. The company is also developing and testing therapeutic products for other autoimmune conditions. Agouron Pharmaceuticals, Inc. was, until July 6, 2001, Immune's partner in developing Remune for commercial distribution and sale. The complaint charges that Immune and Agouron withheld the results of Remune's major clinical trial, and instead hyped the prospects of Remune, even though defendants knew during the Class Period that Remune had no effect upon people with HIV and AIDS. The complaint further alleges defendants' false misrepresentations worked to artificially inflate the price of Immune stock. The Complaint alleges that as a result of the defendants' conduct, plaintiffs and other members of the class suffered damages. Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Weiss & Yourman who has significant experience and expertise in prosecuting class actions on behalf of investors and shareholders. If you are a member of the class described above, you may, no later than September 10, 2001, move the court to serve as lead plaintiff, if you so choose. In order to serve as lead plaintiff, however, you must meet certain legal requirements. For further information please contact Weiss & Yourman (Los Angeles), +1-800-437-7918, Internet: www.wyca.com, E-mail: info@wyca.com SOURCE: Weiss & Yourman